Condition: Recurrent Head and Neck Squamous Cell Carcinoma · Sponsor: Rakuten Medical, Inc.
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn about the safety of ASP-1929 PIT in combination with pembrolizumab. Researchers will compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy (carboplatin or cisplatin, plus 5-fluorouracil or paclitaxel or docetaxel) according to physician's choice (control arm). The overall primary study hypothesis being tested is whether ASP-1929 PIT plus pembrolizumab combination treatment improves the overall survival (OS) of the population defined by the inclusion/exclusion criteria over the control arm.
This description comes directly from the study's public registry record.
ASP-1929-381 Study Team · 858-207-3113 · clinicaltrialinfo@rakuten-med.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Tampa General Hospital | Tampa, Florida, United States | Recruiting |
| University of Kentucky Medical Center | Lexington, Kentucky, United States | Withdrawn |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Rhode Island Hospital | Providence, Rhode Island, United States | Recruiting |
| Avera Cancer Institute | Sioux Falls, South Dakota, United States | Recruiting |
| University of Texas, MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Aichi Cancer Center | Aichi, Japan | Recruiting |
| Hiroshima University Hospital | Hiroshima, Japan | Recruiting |
| Kyoto Prefectural University of Medicine | Kyoto, Japan | Recruiting |
| Tokyo Medical University Hospital | Tokyo, Japan | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06699212